ProductNum | picture | CAS No. | Name and description | Formula | Quick order |
---|---|---|---|---|---|
CL1844A |
|
253128-41-5 |
Eribulin | B1939 | E7389 | ER-086526 98+% |
C40H59NO11 | |
CL1869 |
|
908112-43-6 |
SNX 2112 | PF-04928473 98+% |
C23H27F3N4O3 | |
CL2903B |
|
142373-60-2 |
Tirofiban hydrochloride | L700462 hydrochloride | MK383 hydrochloride) 98+% |
C22H37ClN2O5S | |
CL2903A |
|
144494-65-5 |
Tirofiban | L700462 | MK383 98+% |
C22H36N2O5S | |
CL2903 |
|
150915-40-5 |
Tirofiban Hydrochloride monohydrate | Tirofiban HCl | L700462 hydrochloride monohydrate | MK383 hydrochloride monohydrate 98+% |
C22H39ClN2O6S | |
CL2890 |
|
1228445-38-2 |
Pyrintegrin | PTN 98+% |
C23H25N5O3S | |
CL2726 |
|
796073-69-3 |
DM4 95+% |
C38H54ClN3O10S | |
CL2644 |
|
1642288-47-8 |
Mavacamten (MYK-461) 98+% |
C15H19N3O2 | |
CL1348A |
|
1415246-68-2 |
MMAF Hydrochloride;Monomethylauristatin F Hydrochloride 98+% |
C39H66ClN5O8 | |
CL2467 |
|
1025967-78-5 |
Lifitegrast; SAR 1118 98+% |
C29H24Cl2N2O7S | |
CLA1358 |
|
1342290-43-0 |
Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7) 95+% |
— | |
CLA1352 |
|
1105038-73-0 |
Abituzumab (Anti-Integrin aV / ITGAV / CD51) 95+% |
— | |
CLA1265 |
|
1044758-60-2 |
Etrolizumab (Anti-Integrin α4β7) (ITGA4 & ITGB7) 95+% |
— | |
CLA1226 |
|
339086-79-2 |
Rovelizumab 95+% |
— | |
CLA1211 |
|
211323-03-4 |
Erlizumab (Anti-Integrin b2 / ITGB2 / CD18) 95+% |
— | |
CLA1196 |
|
558480-40-3 |
Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1)) 95+% |
— | |
CLA1185 |
|
892553-42-3 |
Etaracizumab 95+% |
— | |
CLA1118 |
|
143653-53-6 |
Abciximab 95+% |
— | |
CLA1108 |
|
159445-64-4 |
Odulimomab 95+% |
— | |
CLA1097 |
|
142864-19-5 |
Enlimomab 95+% |
— | |